Trial Profile
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) (VENICE II)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms VENICE II
- Sponsors AbbVie
- 01 Feb 2022 Primary endpoint has been met. (Change in Global Health Status/Quality of Life (GHS/QoL) subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30))
- 01 Feb 2022 Results published in the Leukemia and Lymphoma
- 14 Jan 2022 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.